Bristol Myers Squibb 研究负责人将离职,公司合并研发部门
Bristol Myers research chief to depart in ‘evolution’ of company’s structure
百时美施贵宝(Bristol Myers Squibb)将研究与开发部门合并,首席研究官 Robert Plenge 离职,首席医学官 Cristian Massacesi 自 1 月 1 日起出任新设的研发负责人。Plenge 将留任至 2027 年 3 月协助过渡。公司称此次架构“演进”旨在加快决策、改善管线管理并加速管线动能。
Opens in a new window Opens an external website Opens an external website in a new window
This website utilizes technologies such as cookies to enable essential site functionality, as well as for analytics, personalization, and targeted advertising. Privacy Policy
Accept Deny Non-Essential
Storage Preferences
CONTINUE TO SITE ➞
Don’t miss tomorrow’s biopharma industry news
Let BioPharma Dive’s free newsletter keep you informed, straight from your inbox.
Daily Dive M-F
Commercialization Weekly Every Wednesday
Gene Therapy Weekly Every Thursday
Emerging Biotech Weekly Every Tuesday
By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.
Explore our brandsAn Informa TechTarget Publication
- Deep Dive
- Library
- Events
- Press Releases
- Topics
Search
Sign up
Search
People also ask
Loading questions...
An article from
Dive Brief
Bristol Myers research chief to depart in ‘evolution’ of company’s structure
Robert Plenge is leaving as part of a shift that will see the company merge together its R&D department in a bid to speed development and capitalize on new technologies.
Published Nov. 12, 2026
By Kristin Jensen

Entrance sign of the Bristol Myers Squibb office in Summit, N.J., on Aug. 13, 2023. Alamy
Dive Brief:
- Bristol Myers Squibb is combining its research and development departments, elevating Cristian Massacesi to the new job of head of R&D and saying goodbye to Chief Research Officer Robert Plenge, who came to the company with its $74 billion acquisition of Celgene.
- Massacesi, currently chief medical officer and head of development, will take on the new post as of Jan. 1, Bristol Myers said Thursday. Plenge will stay with the company through March 2027 to help with the transition.
- The “evolution” of the research and development organization will help speed decision making, improve portfolio management and “accelerate pipeline momentum,” Bristol Myers said. In the company’s statement, Plenge said he developed the new structure with Massacesi and is “confident it is the right path forward” for the company and patients.
Dive Insight:
Bristol Myers is reorganizing its research department as looming patent expirations threaten the sales of top medicines including the heart drug Eliquis, which brought in more than $14 billion last year.
To find products that can make up for lost sales, Bristol Myers is trying to make the most of drugs in development while looking outside for new prospects as well. There have been a few successes. In August, the company won approval for a multiple myeloma drug called Zenbexus. And another medicine for the condition, mezigdomide, delivered promising results in a study detailed in May.
But there have also been a few stumbles. A research failure set back a bid to widen the use of the heart drug Camzyos last year, and a trial of an experimental lung disease medicine disappointed investors in October. Meanwhile, a much-heralded schizophrenia medicine acquired in a $14 billion takeover of Karuna Therapeuticsfailed in a major study and has generated underwhelming sales so far.
In 2024, Bristol Myers said it would cut 6% of its workforce, consolidate facilities and trim its pipeline in a restructuring designed to strengthen its “long-term growth profile.” The company expanded the cost-cutting program the next year, saying it would slash another $2 billion by the end of 2027.
Since then, Bristol Myers has deepened its investment in artificial intelligence, betting on Anthropic’s Claude tool to tap all of its institutional knowledge. And it has an array of research readouts coming by the end of the first quarter of 2027. “We’ve made meaningful progress with our pipeline, and this evolution is about building on that momentum,” a company spokesperson said Thursday.
Plenge ran the inflammation and immunology business at Celgene before the 2019 acquisition. He then worked his way up in Bristol Myers, becoming head of research in July 2023.
Recommended Reading
Drug patents protect pharma profits. Track when they’ll expire.By Jonathan Gardner • Updated Aug. 4, 2026
Filed Under:Pharma
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
- Select Newsletter: - [x] Daily Dive M-F
- Select Newsletter: - [x] Commercialization Weekly Every Wednesday
- Select Newsletter: - [x] Gene Therapy Weekly Every Thursday
- Select Newsletter: - [x] Emerging Biotech Weekly Every Tuesday
- Select user consent: - [x] By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.
Sign up A valid email address is required. Please select at least one newsletter.
Editors’ picks
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive //Patent thickets
Drug patents protect pharma profits. Track when they’ll expire.
BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.
By Jonathan Gardner • Updated Aug. 4, 2026
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
Tracker
5 FDA decisions to watch in the fourth quarter of 2025
Against the backdrop of a government shutdown, the agency has a series of critical decisions ahead, among them verdicts on new therapies from Novo Nordisk and Biohaven.
By BioPharma Dive staff • Updated Sept. 30, 2025
Get the free newsletter
Subscribe to BioPharma Dive for top news, trends & analysis
Email:
- Select Newsletter: - [x] Daily Dive M-F
- Select Newsletter: - [x] Commercialization Weekly Every Wednesday
- Select Newsletter: - [x] Gene Therapy Weekly Every Thursday
- Select Newsletter: - [x] Emerging Biotech Weekly Every Tuesday
- Select user consent: - [x] By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.
Sign up A valid email address is required. Please select at least one newsletter.
Take your knowledge further with
Sign up for the free newsletter.
Interested? Explore more of what has to offer.
One-click newsletter signup
You’re all set
Thanks for signing up! Please keep an eye out for a confirmation email from newsletter@ittnewsletter.com To ensure we make it into your inbox regularly, add us to your allow list, mark us as a safe sender, or add us to your address book. Check out more from
Most Popular
Drug price hikes in Germany could push US costs higher, study says
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
BIO unveils plan for US to remain biotech’s ‘global leader’
London biotech Oyster harvests $60M for tau-targeting brain drugs
Company Announcements
- Cibus Therapeutics and Greenstone Biosciences Announce First Participant Dosed in Phase 1 Tria… From Greenstone Biosciences Inc
- START Expands its Global Early Phase Cancer Site Network into Italy Through Strategic Partners… From The START Center for Cancer Research
- Axion BioSystems Introduces Synexus, Bringing Richer Functional Insight to Drug Discovery From Axion BioSystems
- CRIO and Eli Lilly and Company win SCDM Innovation Award for Alzheimer’s trial From CRIO
View all | Post a press release
Events
- 16 NOV Webinar | 2 p.m. ET Getting More Value from Factory Automation in MedTech ManufacturingPresented by Studio by Informa TechTarget and Eclipse Automation
- 17 NOV Webinar | 11 a.m. ET Using RWD to Build an ECA With ConfidencePresented by Studio by Informa TechTarget and Flatiron
- 19 NOV Webinar | 2 p.m. ET How to Build a Scalable Local AI Foundation for Agentic Drug DiscoveryPresented by Studio by Informa TechTarget and Dell Technologies
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
- Select Newsletter: - [x] Daily Dive M-F
- Select Newsletter: - [x] Commercialization Weekly Every Wednesday
- Select Newsletter: - [x] Gene Therapy Weekly Every Thursday
- Select Newsletter: - [x] Emerging Biotech Weekly Every Tuesday
- Select user consent: - [x] By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.
Sign up A valid email address is required. Please select at least one newsletter.
Company Announcements
View all | Post a press release
Cibus Therapeutics and Greenstone Biosciences Announce First Participant Dosed in Phase 1 Tria… From Greenstone Biosciences Inc November 11, 2026
START Expands its Global Early Phase Cancer Site Network into Italy Through Strategic Partners… From The START Center for Cancer Research November 03, 2026
Axion BioSystems Introduces Synexus, Bringing Richer Functional Insight to Drug Discovery From Axion BioSystems November 02, 2026
CRIO and Eli Lilly and Company win SCDM Innovation Award for Alzheimer’s trial From CRIO October 27, 2026 
Editors’ picks
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive //Patent thickets
Drug patents protect pharma profits. Track when they’ll expire.
BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.
By Jonathan Gardner • Updated Aug. 4, 2026
Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration
Tracker
5 FDA decisions to watch in the fourth quarter of 2025
Against the backdrop of a government shutdown, the agency has a series of critical decisions ahead, among them verdicts on new therapies from Novo Nordisk and Biohaven.
By BioPharma Dive staff • Updated Sept. 30, 2025
Latest in Pharma
Bayer wins FDA nod for a new kind of blood thinner By Jacob Bell
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma By Jonathan Gardner
Sanofi stops development of Nurix-partnered immune drug By Delilah Alvarado
Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts By Kristin Jensen
Explore
- About
- Editorial Team
- Contact Us
- Newsletter
- Purchase Licensing Rights
- Press Releases
- What We’re Reading
Reach our audience
Related Publications
This website is owned and operated by Informa TechTarget, a global network that informs, influences and connects the world’s technology buyers and sellers.
© 2026 TechTarget, Inc. or its subsidiaries. All rights reserved. An Informa PLC company.
Privacy policy | Terms of use | Take down policy | Cookie Preferences / Do Not Sell
Search
Topics
Get BioPharma Dive in your inbox
The free newsletter covering the top industry headlines
Email:
- Select Newsletter: - [x] Daily Dive M-F
- Select Newsletter: - [x] Commercialization Weekly Every Wednesday
- Select Newsletter: - [x] Gene Therapy Weekly Every Thursday
- Select Newsletter: - [x] Emerging Biotech Weekly Every Tuesday
- Select user consent: - [x] By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.
Sign up A valid email address is required. Please select at least one newsletter.
来源:BioPharma Dive · biopharmadive.com
Informa TechTarget|

